Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry

Alaterre, Elina; Raimbault, Sébastien; Garcia, Jean‐Michel; Rème, Thierry; Requirand, Guilhem; Klein, Bernard; Moreaux, Jérôme

doi:10.1002/cyto.b.21590

Cited by 9 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other hematopoietic malignancies, several automated analysis tools for population identification, diagnostics and detection of minimal residual disease (MRD) are being developed that may provide diagnostic and/or prognostic information with high accuracy. For example, the detection of chronic lymphocytic leukemia, multiple myeloma cells and MRD in multiple myeloma can be automated, as is the case for MRD analysis and subgrouping in AML [55][56][57][58].…”

Section: Implementation In Routine Practicementioning

confidence: 99%

Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes

Duetz¹,

Westers²,

Loosdrecht

2018

Pathobiology

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) are a challenging group of diseases for clinicians and researchers, as both disease course and pathobiology are highly heterogeneous. In (suspected) MDS patients, multi-parameter flow cytometry can aid in establishing diagnosis, risk stratification and choice of therapy. This review addresses the developments and future directions of multi-parameter flow cytometry scores in MDS. Additionally, we propose an integrated diagnostic algorithm for suspected MDS.

show abstract

Section: Implementation In Routine Practicementioning

confidence: 99%

Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes

Duetz¹,

Westers²,

Loosdrecht

2018

Pathobiology

View full text Add to dashboard Cite

show abstract

“…PC and B cells were selected on CD45/CD38 and CD20/CD19 plots, respectively. Abnormal PC were selected based on the CD19, CD27, CD56, CD117, and CD200 signals . 5,000,000 events were acquired per tube and the minimum number of abnormal plasma cells needed was 20.…”

Section: Methodsmentioning

confidence: 99%

“…5,000,000 events were acquired per tube and the minimum number of abnormal plasma cells needed was 20. The maximum sensitivity of the method is 0.0004% . The analyses have been done using FlowJo software (FlowJo, LLC).…”

Section: Methodsmentioning

confidence: 99%

“…Therefore, easy‐to‐perform markers of proliferation remain to be developed for routine practice. Novel multiparameter flow cytometry (MFC) enables increased sensibility and depth of malignant PC detection . Furthermore, assessment of proliferating myeloma cells is of special interest, as proliferating MMCs can be targeted by available treatments and upcoming therapeutic treatment options .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma

Requirand

Naeije

Boireau

et al. 2018

Cytometry Part B Clinical

Self Cite

View full text Add to dashboard Cite

Background Mutiple myeloma (MM) is a neoplasia characterized by the accumulation of malignant plasma cells (PC) in the bone marrow. Although proliferation markers have been studied in MM, none of the current staging systems include them. Moreover, approaches used to analyze proliferation do not separate MM cells (MMCs) from normal PC. Methods In this study, we combined multiparameter flow cytometry and BrdU incorporation or Ki67 staining to analyze MM cell proliferation in 44 monoclonal gammopathy of undetermined significance (MGUS), 153 newly diagnosed MM patients and 69 MM patients at relapse. The prognostic value of proliferation assessment was analyzed in 60 newly diagnosed patients treated with high‐dose chemotherapy supported by autologous hematopoietic stem cell transplantation. Results The median number of proliferating malignant PC significantly increases during MM disease progression. MM patients with a percentage of proliferating MMCs greater than 1.42% using BrdU/DAPI or greater than 1.1% using ki67/DAPI, are associated with a significantly shorter event free survival compared with patients with a lower percentage of proliferating MMCs. Conclusions Combination of flow cytometry with BrdU or ki67/DAPI staining could become a standard for the determination of MM cell proliferation. Furthermore, in the context of new effective myeloma treatment options, assessment of MM cell proliferation may be valuable, in clinical trials, to identify novel agents that could significantly affect the small proliferative compartment of MM cells. © 2018 International Clinical Cytometry Society.

show abstract

“…Elina Alaterre et al from Montpellier report in their manuscript entitled “ Automated and simplified identification of normal and abnormal plasma cells in multiple myeloma by flow cytometry ” on a new simpler and cheaper high‐sensitivity flow cytometric method to analyze bone marrow samples from patients with PCM. They compared their older four tube, 7 color panel with a single tube 5 color panel.…”

Section: Multiple Myelomamentioning

confidence: 99%

Issue Highlights—May 2018 (94B3)

Wallace

2018

Cytometry Part B Clinical

View full text Add to dashboard Cite

show abstract

Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry

Abstract: Our simple and automated strategy for MRD assessment in MM could help increasing reproducibility and productivity without compromising sensitivity and specificity, while decreasing the test cost. © 2017 International Clinical Cytometry Society.

Cited by 9 publications

References 47 publications

Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes

Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes

BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma

Issue Highlights—May 2018 (94B3)

Contact Info

Product

Resources

About